Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US

BACKGROUND: Indacaterol 27.5 µg/glycopyrrolate 15.6 µg (IND/GLY 27.5/15.6 µg) inhalation powder, a twice-daily, fixed-dose combination of a long-acting beta2-agonist (LABA) and a long-acting antimuscarinic antagonist (LAMA), is indicated in the US for long-term maintenance treatment of airflow obstr...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Int J Chron Obstruct Pulmon Dis
Main Authors: Rajagopalan, Krithika, Bloudek, Lisa, Marvel, Jessica, Dembek, Carole, Kavati, Abhishek
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2018
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6276826/
https://ncbi.nlm.nih.gov/pubmed/30568438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S177097
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker